Hikma Pharmaceuticals PLC provided group earnings guidance for the year 2024. For the year, the group expects revenue to grow in the range of 4% to 6%. Core operating profit to be in the range of $660 million to $700 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,913 GBX | +3.18% | +6.34% | +6.93% |
Apr. 26 | HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets | |
Apr. 25 | Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.93% | 5.29B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals PLC Provides Group Earnings Guidance for the Year 2024